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1607-551X/Copyright ª 2015, KaohsiuAbstract The genotypes of hepatitis C virus (HCV) are associated with the therapeutic
response. The racial diversity of Taitung, Taiwan is heterogeneous and a distinguishing feature;
how such racial differences influence the genotype distribution and treatment outcome has
not been well studied. The objective of this study is to elucidate the HCV genotype distribution
in southeastern Taiwan and to analyze the racial differences influencing genotypes and clinical
implications. In this retrospective cohort study, we included 343 patients who had been
treated with peginterferon-alpha plus ribavirin. The predominant HCV genotype in the south-
eastern area was type 1 (43.7%), followed by type 2 (37.0%). The proportion of patients mixed
with genotype 1 was lower in indigenous vis-a`-vis nonindigenous groups (46.1% and 60.2%,
p Z 0.02). The prevalence of genotype 6 (5.2%) seems higher than in the general population
of Taiwan and showed no difference between indigenous and nonindigenous people. The sus-
tained virological response rate was higher in patients without genotype 1, low baseline HCV
RNA ( 400,000 IU/mL), and in patients who achieved rapid virological response. Racial differ-
ences did not influence the therapeutic response. In this retrospective study, the proportion of
HCV genotype 6 appeared slightly higher in southeastern areas than in the general population
in Taiwan. The prevalence of genotype 1 in indigenous people was statistically lower than in
nonindigenous people. Sustained virological response rate did not show any significant differ-
ence between indigenous and nonindigenous people in the current study.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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598 C.-H. Cheng et al.IntroductionHepatitis C virus (HCV) infection is a serious public
health problem worldwide and is a leading cause of chronic
hepatitis, cirrhosis, and even hepatocellular carcinoma.
There are six major genotypes and several subtypes of
HCV. Different genotypes could have various clinical char-
acteristics, histologic severity, and cause the development
of hepatocellular carcinoma. In addition, HCV genotypes
are associated with the therapeutic response to antiviral
agents.
The HCV genotype 1 is common in Australia, China,
Japan, and other countries in North Asia, while genotype 3
is predominant in Thailand, Malaysia, India, and Pakistan.
Genotype 4 is more common in Middle Eastern countries
such as Iraq and Saudi Arabia [1]. HCV genotype 6 is
restricted to South China, Southeast Asia, and in migrant
patients from endemic countries [2]. In Taiwan, the HCV
prevalence is estimated at 4.4% [3,4]. The most common
genotype is 1b, followed by genotype 2a [5,6]. The prev-
alence of HCV genotype 6 is relatively low in Taiwan, ac-
counting for w0.5% of the population [4]. However, a
study of HCV genotype distributions in southern Taiwan
demonstrated a high prevalence of genotype 6 (41.0%)
among injection drug users (IDUs), indicating that the
genotype difference may be influenced by the mode of
viral transmission in Taiwan [7]. The pattern of molecular
epidemiology of HCV in Taiwan is similar to that in Japan
and other countries of Northeastern Asia. Regional dif-
ferences of genotype distribution might exist within
different areas in Taiwan, but the evidence is not well
established.
Taitung is a multiracial county in southeastern Taiwan.
According to the official statement of the Taitung govern-
ment, indigenous people account for > 30% of the popula-
tion in Taitung. There are at least seven indigenous ethnic
tribes found here, including the Bunun, Paiwan, Rukai,
Amis, Beinan, Yamis, and Gamalan.
Racial differences can influence HCV genotype distri-
bution in the world [8,9]. A population study in south
Taiwan showed that HCV genotype 1b had higher preva-
lence (76.9%) in Taoyuan (in a Bunun indigenous commu-
nity) [5]. How racial differences influence HCV genotypes in
Taiwan is not well established.
Antiviral therapy for HCV is expensive and has some
adverse effects. The therapeutic response is influenced by
many predictors, such as age, histological features, dura-
tion of treatment, baseline viral load, and HCV genotypes.
Generally, the sustained viral response (SVR) rate in HCV-1
patients receiving standard peg-interferon (PEG-IFN) plus
ribavirin (RBV) is 54e65% [10], and though not well eluci-
dated, it also might show regional differences in Taiwan
[11,12]. Moreover, some articles have demonstrated that
ethnic differences also play a role in treatment efficacy
[13e15].
In this retrospective cohort study, we analyzed 343 pa-
tients who had been treated with peg-IFN-a plus RBV. The
aim was to investigate the genotype distribution, HCV viral
load, laboratory examination, and the SVR rate. We also
analyzed the relationship of racial differences by HCV ge-
notype and therapeutic response.Methods
Patients and information
We retrospectively reviewed patients with chronic hepatitis
C in Mackay Memorial Hospital, Taitung branch, Taitung,
Taiwan, who were treated according to the Taiwan National
Health Insurance clinical practice guidelines, from
November 2009 to March 2015. The inclusion criteria was
patients older than 20 years with positive anti-HCV and
serum HCV RNA who had received at least a first dose of
PEG-IFN-a plus RBV. After chart review, the HCV genotypes
were analyzed. Many patterns of genotypes have been
discovered in Taitung such as 1aþ2a, 1aþ2b, 1bþ2b, 1þ3,
etc.; therefore, we simply assorted the genotypes into
types 1, 2, 3, 6, 1þ2, 1þ3, and multiple genotypes. The
term “multiple genotypes” means that the patient had
more than two HCV genotypes. All the enrolled HCV pa-
tients were divided into indigenous and nonindigenous
groups. All the 343 HCV patients were included: 92 patients
were treated with PEG-IFN-a-2a (180 mg once weekly), and
the other 251 patients received PEG-IFN-a-2b (1.5 mg/kg
once weekly). All patients with HCV genotypes 1, 4, 5, and 6
received a weight-based RBV (1000 mg/d if < 75 kg or
1200 mg/d if  75 kg); for patients with HCV genotypes 2
and 3, a flat dose of 800 mg/d RBV was prescribed. The
duration of treatment conformed to virological response-
guided therapeutic approaches [16,17]. At the beginning of
treatments, all patients had received at least one session of
therapeutic education with a reference nurse for the
treatment course, possible side effects, and management.
Baseline factors and information were collected, including
age, sex, race, serum anti-HCV antibodies, HCV genotypes,
HCV RNA, aspartate aminotransferase, alanine amino-
transferase, bilirubin, white blood cell, hemoglobin,
platelet, renal functions, and albumin. Data were reported
as mean  standard deviation. HCV genotypes were
detected with primer-specific polymerase chain reaction
(PCR) and direct PCR deep-sequencing with ABI 3730
sequencer. Serum HCV RNA viral loads were quantified using
Roche COBAS AmpliPrep/COBAS TaqMan HCV Test,
Version 2.0 (Roche Molecular Diagnostics, USA) in which the
lowest limit of detection was 15 IU/mL.
Statistical analysis
The continuous data were compared using Student t test
and the categorical variables were compared using Chi-
square test. Several factors were analyzed for the associ-
ation of treatment response with Chi-square test, logistic
regression analysis including odds ratios and respective 95%
confidence intervals. Statistical analyses were performed
using the SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). All
statistical analyses were defined as two-sided hypothesis
with a significance level of p < 0.05.
Definition
The SVR was defined as serum HCV RNA being undetectable
through 24 weeks after cessation of treatment. Rapid
Figure 1. This pie chart demonstrates the hepatitis C virus
genotype distribution in southeastern Taiwan. Genotype 1 was
the most prevalent, followed by genotype 2.
HCV genotype distribution and clinical feature 599virological response (RVR) was defined as undetectable HCV
RNA at Week 4 of treatment. All patients who received the
first course of PEG-IFN plus RBV were included. The pa-
tients without available HCV RNA data after 24 weeks of
completing treatment, or patients who had not completed
the scheduled treatment course due to intolerance of side




In this study, 343 patients who had been treated with PEG-
IFN-a plus RBV were included. Among them, 89 patients
were indigenous and the other 254 patients were nonin-
digenous. The data of genotypes, races, HCV viral load,
laboratory examination, and treatment response were
collected and compared between these two groups. The
clinical characteristics of HCV patients in the indigenous
and nonindigenous groups were similar (p > 0.05) with
respect to sex, mean age, baseline aspartate transaminase,
alanine transaminase, total bilirubin, white cell counts,
hemoglobin, platelet count, albumin, renal functions, and
HCV RNA (Table 1).
HCV genotype distribution
The predominant HCV genotype in the southeastern area
was type 1 (43.7%, including 36.4% of type 1b), followed by
type 2 (37.0%, including 26.8% of type 2a; Figure 1). The
proportion of genotype 1 in the nonindigenous group was
higher than in the indigenous group and, in contrast, the
prevalence of genotype 2 was less in the nonindigenous
group. However, there was no significant difference sta-
tistically (Table 2). We further subdivided the included
patients into two groups: patients mixed with HCVTable 1 Clinical characteristics of hepatitis C virus pa-






Men 39 (43.8) 130 (51.2) 0.71
Age (y) 56.7  9.8 53.1  10.9 0.10
AST (IU/L) 73.7  49.1 81.0  51.4 0.56
ALT (IU/L) 103.4  81.3 109.3  80.2 0.80
Total bilirubin
(mg/dL)
1.0  0.4 1.1  0.5 0.68
WBC (103/mL) 6.6  2.7 5.6  2.0 0.09
Platelet (103/mL) 184.2  57.3 170.8  93.7 0.31
Hb (g/dL) 13.4  1.6 14.0  1.5 0.97
Creatinine (mg/dL) 0.7  0.2 0.8  0.3 0.37
Albumin (g/dL) 3.9  0.5 3.9  0.8 0.58
HCV RNA > 4  105
(IU/mL)
64 (71.9) 178 (70.1) 0.74
Data are presented as n (%) or mean  standard deviation.
ALT Z alanine aminotransferase; AST Z serum aspartate
aminotransferase; Hb Z hemoglobin; HCV Z hepatitis C virus;
WBC Z white blood cell.genotype 1 and without genotype 1. The proportion of HCV
patients mixed with genotype 1 was significantly lower in
indigenous vis-a`-vis nonindigenous groups (46.1% and 60.2%,
p Z 0.02). The prevalence of genotype 6 (5.2%) appeared
slightly higher than in the general population of Taiwan and
showed no difference between indigenous and nonindige-
nous peoples (Figure 1 and Table 2).
Treatment response
For HCV patients who received at least one dose of PEG-IFN-
a plus RBV, the total SVR rate was 70.1% and did not show
significant difference between indigenous and nonindige-
nous groups (Table 3). Univariate analysis showed that the
SVR rate was significantly higher in patients without geno-
type 1, low baseline HCV RNA ( 400,000 IU/mL) and in
patients who achieved RVR. In multivariate logistic regres-
sion analysis, RVR is the only predictor of SVR (odds ratio
1.91, 95% confidence interval 1.14e3.19, p Z 0.014).Table 2 The hepatitis C virus genotypes distribution in
different races.a
Indigenous Nonindigenous
Genotype 1 33 (37.1) 117 (46.1)
2 42 (47.2) 85 (33.5)
3 0 (0) 4 (1.6)
6 6 (6.7) 12 (4.7)
1 þ 2 7 (7.9) 33 (13.0)
1 þ 3 0 (0) 2 (0.8)
Multiple 1 (1.1) 1 (0.4)
Data are presented as n (% within race).
a Each column does not differ significantly from race cate-
gories at p Z 0.05 level.
Table 3 Univariate analysis of factors associated with
sustained viral response.
SVR rate (%) p
Sex Men 71.3 0.90
Women 69.1
Genotype Without genotype1 79.3 0.01
With genotype 1 63.3
Age (y)  55 73.9 0.17
 56 66.1
RVR Achieved 75.9 < 0.001
Not achieved 55.4
HCV RNA (IU/mL)  400,000 77.2 0.05
> 400,000 67.4
Race Indigenous 67.2 0.54
Nonindigenous 71.1
HCV Z hepatitis C virus; RVR Z rapid virological response;
SVR Z sustained virological response.
600 C.-H. Cheng et al.Discussion
The global prevalence of anti-HCV in adults has been esti-
mated at 2.0% (1.7e2.3%). Thirty-one countries, including
Taiwan, accounted for about 80% of global viremic in-
fections [4]. Geographic factors may play a role influencing
the prevalence of the HCV. A previous southern Taiwan
community-based study stated that the estimated preva-
lence of HCV was 4.3% in Taitung and was similar to three
adjacent areas: Kaohsiung County (3.8e5.8%), Pingtung
County (4.6%), and Hualien County (3.6e5.6%) [3,18,19].
There are six major genotypes of HCV, and each con-
tains several subtypes. Significant regional, country, and
local variations have been discovered. In Taiwan, the most
prevalent genotype is 1b (45.5e48.7%), followed by ge-
notypes 2a and 2b [5,6]. As a HCV endemic area, regional
differences of genotype distribution might also exist in
Taiwan [5]. In our study, the most prevalent genotype was
1b, followed by type 2a in southeastern Taiwan. The result
was similar to previous population studies in Taiwan.
However, the proportion of genotype 1 (43.7%) seems
less in southeastern areas and genotype 6 appears more
prevalent (5.2%) than in the general population, though
the statistical difference could not be analyzed in this
study.
The HCV genotype 6 is considered to have originated in
Southeast Asia. It is mainly observed in Vietnam, Laos,
Cambodia, and Thailand. The prevalence of HCV genotype
6 has been reported at 51e54.4% in Vietnam [20,21], while
a study of 106 HCV patients in Laos showed that 95.6% had
genotype 6 [22]. These findings imply that the introduction
of particular HCV isolates might have resulted in the diverse
HCV genotype distribution in different endemic areas in
Taiwan.
The mode of viral transmission may influence the pre-
dominance of certain genotypes. Higher prevalence of HCV
genotype 6 has been reported in IDUs in Taiwan [7,23]. In
our study, there were 18 HCV-6 patients and six (33.3%) of
them had a drug-abuse history. However, in this retro-
spective study, we could not identify all the HCV patients
who were IDUs or not only by chart review.Interestingly, the proportion of HCV genotype 1 is lower
in indigenous people than in nonindigenous people in our
study. This result is opposite to a previous population study
in south Taiwan, which showed a higher prevalence of ge-
notype 1b (76.9%) in the indigenous community in Taoyuan
[5].
Taiwanese indigenous people constitute more than
500,000 people. As a race, they belong to Austronesian
families. The Austronesian people are various populations
in Southeast Asia and Oceania that speak languages of the
Austronesian family [24e26]. Distribution is mainly in the
Southeastern Pacific islands, including Taiwan, southern
Vietnam, Philippines, Malaysia, etc. [26]. The migrations of
Taiwanese indigenous people are believed to bear a close
relationship to the evolution of Austronesian populations
[26e28].
In other Austronesian people, the distribution of HCV
genotypes differs among countries. The most common ge-
notype in the Philippines is 1a (70.7%), followed by type 2
(26.4%). But in Thailand and Malaysia, genotype 3 is the
most prevalent [4]. As mentioned before, the HCV genotype
6 is mainly observed in Vietnam, Laos, and Cambodia. In
New Zealand, the southernmost country of the Austrone-
sian span, the proportion of HCV genotype 1 (55.0%) is
highest, followed by type 3 (35.0%) [4]. In our study, the
proportion of HCV genotype 1 is relatively low in indigenous
people and the prevalence of genotype 6 is slightly higher
than in the general population in Taiwan. Racial differences
and indigenous origins might partially explain this result.
Generally, the genotype distribution did not differ
excessively from other areas in Taiwan. The findings might
derive from frequent HCV inflow into this endemic area and
widespread distribution of HCV between different
countries.
The distribution of HCV genotypes has important clinical
implications, since the treatment regimen, duration, effi-
cacy, and SVR rate differ by genotype. Genotype 1b was
found to have more potent chronicity and liver carcinogen
than other genotypes [29,30].
There are many factors to predict treatment response of
HCV infection, and the strongest predictor is genotypes
[10,31]. Patients with genotypes 1 and 4 have a poorer
response to PEG-IFN plus RBV therapy than those with ge-
notypes 2 and 3. Treatment response in genotype 6 patients
was intermediate between genotype 1 and genotypes 2/3
[2,32]. The likelihood of SVR is directly proportional to the
time of HCV RNA disappearance and the initial HCV RNA
before treatment. According to virological-guided therapy,
if patients have an RVR and low baseline HCV RNA (
400,000 IU/mL), shortening the treatment duration to 24
weeks (genotypes 1 and 4) or 12e16 weeks (genotypes 2/3)
can be considered [16,17]. Besides virological characteris-
tics, host immunity and genetic factors also determine the
disease progression and the outcome of antiviral therapy. In
HCV-1 infection patients, a strong association between the
treatment outcome and a genetic polymorphism near the
interleukin-28B (IL-28B) gene; encoding IFN-lambda-3, has
been elucidated [33,34]. The frequency of favorable IL-28B
polymorphism is higher in Asian patients than European and
African patients [13]. The frequency of rs8099917 TT ge-
notype in Taiwan has been reported substantially higher
than in Swiss Caucasians; patients with TT genotype had
HCV genotype distribution and clinical feature 601significantly higher RVR and SVR rates than those with TG/
GG genotype [11]. Although the global results about the
influence of the IL-28B polymorphism in the treatment of
HCV-2 infection appear dissimilar [34e36], it has been
elucidated that those with favorable alleles had signifi-
cantly higher RVR rates in Taiwan [37]. One study in the
United States also showed that the SVR rates were highest
in Asian American patients, followed by white, Hispanic,
and African Americans [15]; it also emphasized the role of
race and host factors in treatment of HCV patients. In our
study, the overall SVR rate in HCV-1 patients was 63.3%.
Several factors may contribute to the result: IL-28B genetic
variants, local ethnic diversity, or other etiologies not yet
discovered. However, racial differences did not signifi-
cantly influence the treatment outcome in the present
study, and this result is in concordance with a previous
study [12]. The Taiwanese National Health Insurance sys-
tem does not supply any test for IL-28B polymorphisms,
therefore, such tests were not performed in our study.
In the present study, both genotypes mixed without type
1, low HCV RNA, and patients achieving RVR were pre-
dictors of better SVR rate in univariate analysis. This result
is not surprising to physicians based on previous current
treatment experience and articles published. The issue we
were interested in was whether racial differences influ-
enced treatment outcome or not; although, no significant
statistical difference was found in the current study. High
frequency of HCV inflow in this area has led to the mixture
of initially highly diverse viruses in different races. This
could partially explain the consequence that the treatment
outcome did not differ between each group. There are
some limitations in our article. This is a retrospective study
including a small size of HCV patients. We could not
distinguish all the included patients who were IDU or not
only by chart review, so the influence of transmission route
with HCV genotype distribution could not be clearly dis-
cussed. In addition, the tests of IL28B polymorphism were
not performed; therefore, we could not distinguish clearly
how IL28B genotype variants affected treatment response
in different races.
In this retrospective study, HCV genotype 6 seems more
common in southeastern areas than in the general popula-
tion in Taiwan. The prevalence of genotype 1 in indigenous
people is lower than in nonindigenous people. These find-
ings might be partially explained by the similar origin of our
indigenous people and other global Austronesian people,
but the association is not well established. The SVR rate
showed no significant difference between indigenous and
nonindigenous peoples in the present article. For further
investigation, larger population studies might provide more
information about these issues.References
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